NasdaqCM - Delayed Quote USD

Citius Pharmaceuticals, Inc. (CTXR)

0.8055 -0.0107 (-1.31%)
At close: April 18 at 4:00 PM EDT
0.7980 -0.01 (-0.93%)
Pre-Market: 7:24 AM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Leonard L. Mazur Co-Founder, CEO, Chairman & Secretary 676.88k -- 1945
Mr. Myron Z. Holubiak Co-Founder & Executive Vice Chairman 641.25k -- 1947
Dr. Myron S. Czuczman M.D. Executive VP & Chief Medical Officer 571.38k -- 1960
Mr. Jaime Bartushak Chief Business Officer, CFO & Chief Accounting Officer 527.97k -- 1968
Mr. Gary F. Talarico Executive Vice President of Operations -- -- 1955
Ms. Ilanit Allen Vice President of Investor Relations & Corporate Communications -- -- --
Dr. Alan Lader Ph.D. Senior VP and Head of Clinical Operations & Quality Assurance -- -- --
Mr. Dhananjay G. Wadekar Senior Vice President of Business Strategy -- -- 1954
Mr. Kelly Creighton Ph.D. Executive Vice President of Chemistry, Manufacturing & Controls -- -- --
Mr. Nikolas Burlew Executive Vice President of Quality Assurance -- -- --

Citius Pharmaceuticals, Inc.

11 Commerce Drive
First Floor
Cranford, NJ 07016
United States
908 967 6677 https://citiuspharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
22

Description

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Corporate Governance

Citius Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 1; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 10, 2024 - May 14, 2024
Citius Pharmaceuticals, Inc. Earnings Call

Related Tickers

XFOR X4 Pharmaceuticals, Inc.
1.2000
+0.42%
 
ADAP Adaptimmune Therapeutics plc
0.8984
-8.98%
 
CVM CEL-SCI Corporation
1.5000
0.00%
 
ATOS Atossa Therapeutics, Inc.
1.4200
+5.19%
 
EYEN Eyenovia, Inc.
0.5309
-1.56%
 
TNXP Tonix Pharmaceuticals Holding Corp.
0.1570
-1.51%
 
AKBA Akebia Therapeutics, Inc.
1.3900
0.00%
 
ATNM Actinium Pharmaceuticals, Inc.
6.67
-8.00%
 
SLS SELLAS Life Sciences Group, Inc.
1.5200
+7.80%
 
CRMD CorMedix Inc.
5.42
-0.37%